VXRT.OOTC
- Vaxart, Inc.
报价延迟最少15分钟:2026/01/20 00:25 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.7017 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.22/-0.54
|
|
企业价值
170.49M
|
| 资产负债 |
|
每股账面净值
0.11
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
892.00K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||
|
||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States. |
